Cargando…

CoCoss-Trial: Concurrent Comparison of Self-Sampling Devices for HPV-Detection

High-risk human papillomavirus (hr-HPV) infection of the cervicovaginal tract is known to be the major cause of cervical cancer. Similar to various other countries, Germany introduced an organized combined screening including cytology and HPV testing in 2020. The participation rate was around 70% in...

Descripción completa

Detalles Bibliográficos
Autores principales: Ertik, Faruk Cem, Kampers, Johanna, Hülse, Fabienne, Stolte, Claudia, Böhmer, Gerd, Hillemanns, Peter, Jentschke, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508434/
https://www.ncbi.nlm.nih.gov/pubmed/34639688
http://dx.doi.org/10.3390/ijerph181910388
_version_ 1784582096514187264
author Ertik, Faruk Cem
Kampers, Johanna
Hülse, Fabienne
Stolte, Claudia
Böhmer, Gerd
Hillemanns, Peter
Jentschke, Matthias
author_facet Ertik, Faruk Cem
Kampers, Johanna
Hülse, Fabienne
Stolte, Claudia
Böhmer, Gerd
Hillemanns, Peter
Jentschke, Matthias
author_sort Ertik, Faruk Cem
collection PubMed
description High-risk human papillomavirus (hr-HPV) infection of the cervicovaginal tract is known to be the major cause of cervical cancer. Similar to various other countries, Germany introduced an organized combined screening including cytology and HPV testing in 2020. The participation rate was around 70% in the past. Self-testing for hr-HPV infections could be an option to increase the participation rate. Two dry vaginal self-sampling devices and a device for the self-collection of first-void urine were evaluated in combination with a PCR-based hr-HPV test regarding their clinical performance (sensitivity for high-grade cervical intraepithelial neoplasia, CIN 2+). A cervical smear taken by a clinician during colposcopy was used as reference. This open prospective multicenter trial recruited patients referred to the two participating colposcopy clinics (Hannover Medical School and IZD Hannover, Germany) with abnormal results from cervical cancer screening from 05/2020 to 11/2020. All patients received three CE-certified self-sampling devices (FLOQSwabs, COPAN, Italy; Evalyn Brush, Rovers Medical Devices, the Netherlands; Colli-Pee FV-5000, Novosanis, Wijnegem, Belgium) with instructions to read and apply at home in a pre-specified alternating order without medical assistance. HPV testing was performed after adequate preservation and DNA extraction. Histological results from colposcopy or cervical excisional surgery after self-sampling were used as the gold-standard. The data of 65 patients were analyzed. All invasive cancer cases and over 90% of the CIN 3 lesions were found to be hr-HPV positive with all three self-collection devices. All devices were considered easy to use without any difficulties following the written instructions. Hr-HPV testing of self-collected first-void urine and dry vaginal self-samples showed a high sensitivity for CIN 3+ comparable to that of a clinician-taken smear. Self-sampling was well accepted as it is convenient and easy to use.
format Online
Article
Text
id pubmed-8508434
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85084342021-10-13 CoCoss-Trial: Concurrent Comparison of Self-Sampling Devices for HPV-Detection Ertik, Faruk Cem Kampers, Johanna Hülse, Fabienne Stolte, Claudia Böhmer, Gerd Hillemanns, Peter Jentschke, Matthias Int J Environ Res Public Health Article High-risk human papillomavirus (hr-HPV) infection of the cervicovaginal tract is known to be the major cause of cervical cancer. Similar to various other countries, Germany introduced an organized combined screening including cytology and HPV testing in 2020. The participation rate was around 70% in the past. Self-testing for hr-HPV infections could be an option to increase the participation rate. Two dry vaginal self-sampling devices and a device for the self-collection of first-void urine were evaluated in combination with a PCR-based hr-HPV test regarding their clinical performance (sensitivity for high-grade cervical intraepithelial neoplasia, CIN 2+). A cervical smear taken by a clinician during colposcopy was used as reference. This open prospective multicenter trial recruited patients referred to the two participating colposcopy clinics (Hannover Medical School and IZD Hannover, Germany) with abnormal results from cervical cancer screening from 05/2020 to 11/2020. All patients received three CE-certified self-sampling devices (FLOQSwabs, COPAN, Italy; Evalyn Brush, Rovers Medical Devices, the Netherlands; Colli-Pee FV-5000, Novosanis, Wijnegem, Belgium) with instructions to read and apply at home in a pre-specified alternating order without medical assistance. HPV testing was performed after adequate preservation and DNA extraction. Histological results from colposcopy or cervical excisional surgery after self-sampling were used as the gold-standard. The data of 65 patients were analyzed. All invasive cancer cases and over 90% of the CIN 3 lesions were found to be hr-HPV positive with all three self-collection devices. All devices were considered easy to use without any difficulties following the written instructions. Hr-HPV testing of self-collected first-void urine and dry vaginal self-samples showed a high sensitivity for CIN 3+ comparable to that of a clinician-taken smear. Self-sampling was well accepted as it is convenient and easy to use. MDPI 2021-10-02 /pmc/articles/PMC8508434/ /pubmed/34639688 http://dx.doi.org/10.3390/ijerph181910388 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ertik, Faruk Cem
Kampers, Johanna
Hülse, Fabienne
Stolte, Claudia
Böhmer, Gerd
Hillemanns, Peter
Jentschke, Matthias
CoCoss-Trial: Concurrent Comparison of Self-Sampling Devices for HPV-Detection
title CoCoss-Trial: Concurrent Comparison of Self-Sampling Devices for HPV-Detection
title_full CoCoss-Trial: Concurrent Comparison of Self-Sampling Devices for HPV-Detection
title_fullStr CoCoss-Trial: Concurrent Comparison of Self-Sampling Devices for HPV-Detection
title_full_unstemmed CoCoss-Trial: Concurrent Comparison of Self-Sampling Devices for HPV-Detection
title_short CoCoss-Trial: Concurrent Comparison of Self-Sampling Devices for HPV-Detection
title_sort cocoss-trial: concurrent comparison of self-sampling devices for hpv-detection
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508434/
https://www.ncbi.nlm.nih.gov/pubmed/34639688
http://dx.doi.org/10.3390/ijerph181910388
work_keys_str_mv AT ertikfarukcem cocosstrialconcurrentcomparisonofselfsamplingdevicesforhpvdetection
AT kampersjohanna cocosstrialconcurrentcomparisonofselfsamplingdevicesforhpvdetection
AT hulsefabienne cocosstrialconcurrentcomparisonofselfsamplingdevicesforhpvdetection
AT stolteclaudia cocosstrialconcurrentcomparisonofselfsamplingdevicesforhpvdetection
AT bohmergerd cocosstrialconcurrentcomparisonofselfsamplingdevicesforhpvdetection
AT hillemannspeter cocosstrialconcurrentcomparisonofselfsamplingdevicesforhpvdetection
AT jentschkematthias cocosstrialconcurrentcomparisonofselfsamplingdevicesforhpvdetection